Moderna Inc. (NASDAQ: MRNA) reported total revenue of $5.1 billion for the fourth quarter of 2022, down 29% year-over-year due to a drop in COVID-19 vaccine sales.
Net income decreased by 70% to $1.5 billion while EPS dropped by 68% to $3.61 compared to the same period last year.
The company expects product sales of approx. $2 billion in the first half of 2023.
Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!
Most Popular
Key takeaways from Cintas’ (CTAS) third-quarter 2023 report
Cintas Corporation (NASDAQ: CTAS) has been growing its market share by diversifying into new areas and through acquisitions. The prudent business model, with a focus on recurring revenues, has helped
Here are a few points to keep in mind if you are considering Starbucks Corporation (SBUX)
Shares of Starbucks Corporation (NASDAQ: SBUX) stayed in green on Thursday. The stock has gained 10% over the past 12 months. The company delivered healthy results for its most recent
ANGO Earnings: AngioDynamics reports loss for Q3; revenue up 9%
AngioDynamics Inc. (NASDAQ: ANGO) on Thursday reported a wider loss for the third quarter when the medical device maker's revenues increased by 9%. The company also provided guidance for fiscal
